Haemonetics Corporation 10-Q Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and six months ended October 1, 2005 (Fiscal Year 2006)
Business Overview: Haemonetics designs, manufactures, and markets automated systems for the collection, processing, and surgical salvage of donor and patient blood. The company operates in one segment with two product families: Donor products (Plasma, Blood Bank, Red Cell) and Patient products (Surgical blood salvage).
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Oct 1, 2005 | 3 Months Ended Oct 2, 2004 | 6 Months Ended Oct 1, 2005 | 6 Months Ended Oct 2, 2004 |
|---|---|---|---|---|
| Net Revenues | $100,488 | $90,923 | $203,661 | $185,525 |
| Gross Profit | $51,765 | $45,549 | $106,289 | $92,649 |
| Gross Margin | 51.5% | 50.1% | 52.2% | 49.9% |
| Operating Income | $15,379 | $13,911 | $33,874 | $28,873 |
| Net Income | $10,945 | $8,874 | $23,829 | $18,694 |
| Diluted EPS | $0.40 | $0.34 | $0.87 | $0.73 |
| Cash & Equivalents | $209,981 (as of Oct 1, 2005) | |||
| Working Capital | $291,161 (as of Oct 1, 2005) | |||
| Total Debt | $46,610 (Current: $27,643; Long-term: $18,967) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 10.5% for the quarter and 9.8% for the six-month period. Growth was driven by increases in disposable, software, and equipment revenues. Foreign exchange rates contributed approximately 2.6% to the quarterly revenue increase.
- Product Performance:
- Donor Products: Red Cell disposable revenue surged 33.8% (quarter) and 32.4% (six months), primarily due to U.S. sales of filtered units. Plasma revenue grew 7.0% (quarter). Blood Bank revenue declined 3.4% (quarter) due to lower U.S. sales of intravenous solutions and fewer platelet collections in Japan.
- Patient Products: Surgical disposable revenue was flat (-0.6%) for the quarter but grew 4.4% for the six months. OrthoPAT revenue increased, while Cell Saver revenue declined slightly.
- Equipment & Service: Equipment revenue jumped 156.7% for the quarter, driven by military sales and the new Cell Saver 5+ device. Miscellaneous and Service revenue rose 69.6%, largely due to software support contracts.
- Expenses: Operating expenses increased 15.0% for the quarter. Research and Development (R&D) spending rose 47.7% due to new product development (multi-component collection platform). Selling, General, and Administrative (SG&A) expenses increased 9.9% due to higher personnel costs and legal fees.
- Profitability: Net income increased 23.3% for the quarter and 27.5% for the six months. Without favorable foreign exchange effects, operating income would have decreased 7.8% for the quarter due to higher R&D and SG&A costs.
Guidance, Outlook, Risks, and Unusual Items
- Subsequent Event (Arbitration Win): On October 6, 2005, an arbitration panel awarded Haemonetics $27.8 million in damages plus interest and fees against Baxter International, Inc. On October 13, 2005, the company received $30.8 million in full satisfaction. This award is expected to increase pre-tax income by $28.1 million in the third quarter of fiscal 2006.
- Product Delays & Recalls:
- cardioPAT: The company voluntarily recalled 33 devices due to a potential valve issue on the disposable. A design change is being implemented at an estimated cost of $0.2 million.
- CritScan: Launch of this non-invasive hematocrit testing device has been delayed as it is not meeting quality standards in initial trials.
- Accounting Changes: The company must adopt SFAS No. 123R (Share-Based Payments) in fiscal 2007, which will require expensing stock options based on fair value, significantly impacting reported earnings. Pro forma EPS for the six months ended Oct 1, 2005, would have been $0.76 (diluted) under this standard versus $0.87 reported.
- Foreign Exchange Risk: Approximately 63% of sales are generated outside the U.S. (primarily Japan and Europe). The company uses forward contracts to hedge currency exposure. A strengthening U.S. dollar negatively impacts results, while a weakening dollar provides a favorable effect.
- Liquidity: The company maintains a strong net cash position of $163.4 million. Management believes internal cash flows and existing credit facilities are sufficient to fund operations for the next 12 months.
Investor Verification Checklist
- Arbitration Proceeds: Verify the timing and tax treatment of the $30.8 million Baxter award in the upcoming Q3 2006 filing.
- Stock-Based Compensation Impact: Monitor the company's selection of transition methods for SFAS No. 123R adoption in fiscal 2007, as this will materially reduce reported net income.
- Product Launches: Track the regulatory approval status and market launch of the corrected cardioPAT device and the delayed CritScan technology.
- Foreign Exchange Sensitivity: Assess the impact of current Yen and Euro exchange rates on future revenue and gross margins, given the high percentage of international sales.
- Inventory Levels: Review inventory turnover trends, as inventory increased by $4.5 million in the first six months, contributing to a decrease in operating cash flow.